摘要
目的:观察替米沙坦治疗前后原发性高血压(EH)患者血清脂联素和颈动脉内膜中层厚度(IMT)的变化。方法:选取52例高血压患者(高血压组)和50例健康体检者(对照组)为研究对象。高血压组接受替米沙坦治疗6个月后,观察对照组及高血压组治疗前后的血压、脂联素、胰岛素、颈动脉IMT等指标的变化情况。结果:与对照组比较,高血压组的血压、颈动脉IMT升高,脂联素水平降低,差异有统计学意义(P<0.05)。与治疗前比较,高血压组治疗6个月后血压显著降低(P<0.01),高敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、颈动脉IMT显著下降(P<0.05),脂联素水平显著升高(P<0.05),胰岛素、胰岛素抵抗得到显著改善(P<0.01)。血清脂联素水平与胰岛素抵抗程度、颈动脉IMT均呈负相关。结论:替米沙坦显著增高原发性高血压患者血清脂联素水平,改善胰岛素抵抗,抑制颈动脉粥样硬化的进展。
Objective：To investigate the effect of telmisartan on adiponectin and carotid artery intima-media thickness（CIMT）in patients with essential hypertension（EH）.Method：The 52 patients with EH（EH group）and 50 healthy people（control group）were enrolled in this study.Patients received treatment with telmisartan for 6 months.The serum concentrations of fasting adiponectin,insulin,blood pressure and carotid IMT were detected and analyzed comparatively in EH group at baseline and after treatment and control group.Result：CIMT and Blood pressure increased significantly and the serum adiponectin levels decreased significantly in EH group compared with those in control group（P〈0.05,respectively）.After the treatment in EH group,the serum hs-CRP（P〈0.05）,TNF-α（P〈0.05）and insulin levels（P〈0.01）,blood pressure（P〈0.01）,HOMA-IR（P〈0.01）and CIMT（P〈0.05）were significantly decreased,but serum adiponectin（P〈0.05）was significantly increased compared with those before the treatment.There was negative correlation between the serum adiponectin level and CIMT or HOMA-IR.Conclusion：Telmisartan could improve adiponectin and IR and inhibit the progression of CIMT in patients with essential hypertension.
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2015年第11期1192-1194,共3页
Journal of Clinical Cardiology
基金
河南省科技厅基金项目(No:132102310166)
关键词
高血压
替米沙坦
脂联素
颈动脉粥样硬化
hypertension
telmisartan
adiponectin
carotid artery atherosclerosis
